Refisolone
pharmaceutical compound
Refisolone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names PH-80, Salubrin, and ORG-39479), also known as 10-hydroxy-16α,17α-epoxyestr-4-en-3-one, is a vomeropherine (pherine) which is under development for the treatment of hot flashes, migraine, and premenstrual dysphoric disorder (PMDD). It is taken intranasally as a nasal spray. The pharmacology of refisolone has been studied and reported. The drug is under development by Pherin Pharmaceuticals and VistaGen Therapeutics, with the former having been acquired by the latter in 2023. As of December 2025, refisolone is in phase 2 clinical trials for all indications. However, a phase 3 trial of refisolone for PMDD is also reported to have been registered in 2015, though its status is listed as unknown.
The public source identifies “Refisolone” as pharmaceutical compound. This brief keeps that definition visible, then builds a research path around Refisolone, pharmaceutical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Refisolone”, the useful work is to connect “pharmaceutical compound” to the records capable of establishing context and consequence.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Mar 11, 2026. The linked authority identifier is Q138775839. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2023, 2025 and 2015.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Refisolone”, its source revision and the description used here.
- Expand the search: follow Refisolone primary sources, Refisolone archive and Refisolone research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Refisolone”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Refisolone” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.